|
1
|
Norden AD, Drappatz J and Wen PY:
Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol.
5:610–620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jain RK: Normalization of tumor
vasculature: An emerging concept in antiangiogenic therapy.
Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goel S, Duda DG, Xu L, Munn LL, Boucher Y,
Fukumura D and Jain RK: Normalization of the vasculature for
treatment of cancer and other diseases. Physiol Rev. 91:1071–1121.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang R, Chadalavada K, Wilshire J, Kowalik
U, Hovinga KE, Geber A, Fligelman B, Leversha M, Brennan C and
Tabar V: Glioblastoma stem-like cells give rise to tumor
endothelium. Nature. 468:829–833. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wolburg H, Noell S, Fallier-Becker P, Mack
AF and Wolburg-Buchholz K: The disturbed blood-brain barrier in
human glioblastoma. Mol Aspects Med. 33:579–589. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mrugala MM: Advances and challenges in the
treatment of glioblastoma: A clinician's perspective. Discov Med.
15:221–230. 2013.PubMed/NCBI
|
|
7
|
Gerstner ER and Batchelor TT:
Antiangiogenic therapy for glioblastoma. Cancer J. 18:45–50. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pàez-Ribes M, Allen E, Hudock J, Takeda T,
Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D and Casanovas O:
Antiangiogenic therapy elicits malignant progression of tumors to
increased local invasion and distant metastasis. Cancer cell.
15:220–231. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bazzoni G and Dejana E: Endothelial
cell-to-cell junctions: Molecular organization and role in vascular
homeostasis. Physiol Rev. 84:869–901. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mehta D and Malik AB: Signaling mechanisms
regulating endothelial permeability. Physiol Rev. 86:279–367. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takai Y, Ikeda W, Ogita H and Rikitake Y:
The immunoglobulin-like cell adhesion molecule nectin and its
associated protein afadin. Annu Rev Cell Dev Biol. 24:309–342.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mandai K, Nakanishi H, Satoh A, Obaishi H,
Wada M, Nishioka H, Itoh M, Mizoguchi A, Aoki T, Fujimoto T, et al:
Afadin: A novel actin filament-binding protein with one PDZ domain
localized at cadherin-based cell-to-cell adherens junction. J Cell
Biol. 139:517–528. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ogita H, Rikitake Y, Miyoshi J and Takai
Y: Cell adhesion molecules nectins and associating proteins:
Implications for physiology and pathology. Proc Jpn Acad Ser B Phys
Biol Sci. 86:pp. 621–629. 2010; View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Su Li, Hattori M, Moriyama M, Murata N,
Harazaki M, Kaibuchi K and Minato N: AF-6 controls
integrin-mediated cell adhesion by regulating Rap1 activation
through the specific recruitment of Rap1GTP and SPA-1. J Biol Chem.
278:15232–15238. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Elloul S, Kedrin D, Knoblauch NW, Beck AH
and Toker A: The adherens junction protein afadin is an AKT
substrate that regulates breast cancer cell migration. Mol Cancer
Res. 12:464–476. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Takai Y and Nakanishi H: Nectin and
afadin: Novel organizers of intercellular junctions. J Cell Sci.
116:17–27. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Arcaro A and Guerreiro AS: The
phosphoinositide 3-kinase pathway in human cancer: Genetic
alterations and therapeutic implications. Curr Genomics. 8:271–306.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McDowell KA, Riggins GJ and Gallia GL:
Targeting the AKT pathway in glioblastoma. Curr Pharm Des.
17:2411–2420. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Keunen O, Johansson M, Oudin A, Sanzey M,
Rahim SA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, et al:
Anti-VEGF treatment reduces blood supply and increases tumor cell
invasion in glioblastoma. Proc Natl Acad Sci USA. 108:pp.
3749–3754. 2011; View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah
G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I,
Nagy JA, et al: Pathological angiogenesis is induced by sustained
Akt signaling and inhibited by rapamycin. Cancer cell. 10:159–170.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhai X, Liang P, Li Y, Li L, Zhou Y, Wu X,
Deng J and Jiang L: Astrocytes regulate angiogenesis through the
Jagged1-mediated notch1 pathway after status epilepticus. Mol
Neurobiol. 53:5893–5901. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Eccles SA: Parallels in invasion and
angiogenesis provide pivotal points for therapeutic intervention.
Int J Dev Biol. 48:583–598. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dejana E, Tournier-Lasserve E and
Weinstein BM: The control of vascular integrity by endothelial cell
junctions: Molecular basis and pathological implications. Dev Cell.
16:209–221. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wallez Y and Huber P: Endothelial adherens
and tight junctions in vascular homeostasis, inflammation and
angiogenesis. Biochim Biophys Acta. 1778:794–809. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Posada-Duque RA, Barreto GE and
Cardona-Gomez GP: Protection after stroke: Cellular effectors of
neurovascular unit integrity. Front Cell Neurosci. 8:2312014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dudley AC: Tumor endothelial cells. Cold
Spring Harb Perspect Med. 2:a0065362012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Severson EA, Lee WY, Capaldo CT, Nusrat A
and Parkos CA: Junctional adhesion molecule a interacts with afadin
and PDZ-GEF2 to activate Rap1A, regulate beta1 integrin levels and
enhance cell migration. Mol Biolo Cell. 20:1916–1925. 2009.
View Article : Google Scholar
|
|
29
|
Fournier G, Cabaud O, Josselin E, Chaix A,
Adélaïde J, Isnardon D, Restouin A, Castellano R, Dubreuil P,
Chaffanet M, et al: Loss of AF6/afadin, a marker of poor outcome in
breast cancer, induces cell migration, invasiveness and tumor
growth. Oncogene. 30:3862–3874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tawa H, Rikitake Y, Takahashi M, Amano H,
Miyata M, Satomi-Kobayashi S, Kinugasa M, Nagamatsu Y, Majima T,
Ogita H, et al: Role of afadin in vascular endothelial growth
factor-and sphingosine 1-phosphate-induced angiogenesis. Cir Res.
106:1731–1742. 2010. View Article : Google Scholar
|
|
31
|
Karar J and Maity A: PI3K/AKT/mTOR pathway
in angiogenesis. Front Mol Neurosci. 4:512011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Prasad G, Sottero T, Yang X, Mueller S,
James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, et al:
Inhibition of PI3K/mTOR pathways in glioblastoma and implications
for combination therapy with temozolomide. Neuro Oncol. 13:384–392.
2011. View Article : Google Scholar : PubMed/NCBI
|
